Recruiting nowPhase 1Interventional
What this study is about
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 30 to 39 weeks (7 to 10 months).
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 65 Years
SexAll
Healthy volunteersAccepted
ConditionObesity, Overweight
Full registry criteria
Inclusion Criteria: * Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease * Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m² * Have had a self-reported stable weight for 3 months prior to screening Exclusion Criteria: * Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data * Is an individual of childbearing potential (IOCBP)
Primary outcomes
Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationBaseline through end of the Follow-up (Week 25)A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.
Part B: Number of Participants with One or More TEAEs and SAEs Considered by the Investigator to be Related to Study Drug AdministrationBaseline through end of the Follow-up (Week 33)A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.
